Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial

Autor: Gilmar Reis, Jose Nicolau, Andrzej Rynkiewicz, Simon Jones, Giovanni ESPOSITO, Konstantin Ramshev, James Spratt, Marco Vugman Wainstein, Miguel Urina, Furio Colivicchi, Legkonogov Aleksandr, Yury Shvarts, Carole Siegel, Yury Grinshtein, Diana Gorog, Ricardo Bohorquez, Alexander Joost, Aldo Pietro Maggioni, Peter Sinnaeve, Crina Julieta Sinescu, Prof. Dr. Ahmed Nahhas, Judith Hochman, Leszek Gromadziński, Catalina Arsenescu Georgescu, Mónica Jaramillo, Nattawut Wongpraparut, Filipa Costa, Yaroslav Malynovsky, Philippe Gabriel STEG, Gianluca Campo, Vladimir Zadionchenko, Andreas Zirlik, Jerome Chin, Wolfram Goessling, Daniel Pella, Roman Libis, Ivo Petrov, Giuseppe Giugliano, Glenn Hamroff, Sergei Shalaev, Amos Katz, Meyer ELBAZ, Peter Ganz, Martha Sarno, Wolfgang Koenig, ADISAI BUAKHAMSRI, Marco Valgimigli, Simcha Meisel, Svetlana Boldueva, K Srinath Reddy, FRANCISCO FUENTES JIMENEZ, Raúl J. Gazmuri, Philip Aylward, Albert Vernon Smith, Fernando Manzur, Dmitry Zateyshchikov, Zuyi Yuan, William Wijns, Arman Postadzhiyan, Arun Chopra, Andrzej Budaj, Pablo Olavegogeascoechea, Emilia Solinas

Publikováno v: JAMA-Journal of the American Medical Association, 312(10), 1006-1015. American Medical Association
JAMA, 312(10), 1006-1015. American Medical Association
JAMA : the journal of the American Medical Association

IMPORTANCE: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme. OBJECTIVE: To evaluate the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1e3aa462792e6e3513431e7f9c25697
https://pubmed.ncbi.nlm.nih.gov/25223450